Abstract
Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.
Keywords: Artemisinin, malaria, quinine, treatment.
Infectious Disorders - Drug Targets
Title:Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Volume: 13 Issue: 4
Author(s): Philip Botha, Emmanuel Bottieau, Olalekan Uthman, Ude Obike and Jean B. Nachega
Affiliation:
Keywords: Artemisinin, malaria, quinine, treatment.
Abstract: Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.
Export Options
About this article
Cite this article as:
Botha Philip, Bottieau Emmanuel, Uthman Olalekan, Obike Ude and Nachega B. Jean, Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations, Infectious Disorders - Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/1871526513666140103122630
DOI https://dx.doi.org/10.2174/1871526513666140103122630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety The Complexes of Drugs with Carbohydrate-Containing Plant Metabolites as Pharmacologically Promising Agents
Mini-Reviews in Medicinal Chemistry Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Evaluation of Allergic Reactions Following Intravenous Infusion of Polyvalent Antivenom in Snakebite Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Cutaneous Neurovascular Interaction Involved in Tactile Sensation
Cardiovascular & Hematological Agents in Medicinal Chemistry An Efficient Multiple Kernel Support Vector Regression Model for Assessing Dry Weight of Hemodialysis Patients
Current Bioinformatics Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease
Mini-Reviews in Medicinal Chemistry